PPARAgonist GW501516 Inhibits PDGF-Stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling
Open Access
- 1 January 2013
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2013, 1-8
- https://doi.org/10.1155/2013/903947
Abstract
Pulmonary arterial hypertension (PAH) is a severe and progressive disease, a key feature of which is pulmonary vascular remodeling. Growth factors, cytokines, and lipid mediators are involved in this remodeling process. Recent reports suggest that the peroxisome proliferator-activated receptors (PPARs) play important roles in the regulation of cell growth and differentiation as well as tissue wounding and repair. In this study, we examined the role of PPARδin the regulation of proliferation, migration, collagen synthesis, and chemokine production in human pulmonary arterial smooth muscle cells (HPASMCs). The data showed that PPARδwas the most abundant isoform in HPASMCs. PPARδwas upregulated in HPASMCs treated with PDGF, which is the major mediator in pulmonary vascular remodeling. Activation of PPARδby GW501516, a specific PPARδligand, significantly inhibited PDGF-induced proliferation in HPASMCs. The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and. Pretreatment of HPASMCs with GW501516 significantly inhibited PDGF-induced cell migration and collagen synthesis. GW501516 also significantly attenuated TNF-mediated expression of MCP-1. These results suggest that PPARδmay be a potential therapeutic target against the progression of vascular remodeling in PAH.
Keywords
Funding Information
- Scientific Research Foundation for Returned Scholars (11JCYBJC27200, 81170828)
This publication has 40 references indexed in Scilit:
- GW501516, a PPARδ Agonist, Ameliorates Tubulointerstitial Inflammation in Proteinuric Kidney Disease via Inhibition of TAK1-NFκB Pathway in MicePLOS ONE, 2011
- Control of Macrophage Activation and Function by PPARsCirculation Research, 2010
- Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertensionJournal Of Hypertension, 2010
- PPARs and the Cardiovascular SystemAntioxidants and Redox Signaling, 2009
- Regulation of epithelial–mesenchymal IL-1 signaling by PPARβ/δ is essential for skin homeostasis and wound healingThe Journal of cell biology, 2009
- Ligand Activation of Peroxisome Proliferator-Activated Receptor-β/δ Inhibits Cell Proliferation in Human HaCaT KeratinocytesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- Molecular pathogenesis of pulmonary arterial hypertensionJCI Insight, 2008
- Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in miceBiochemical and Biophysical Research Communications, 2008
- Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancerJournal of Cellular Physiology, 2007
- Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progressionProceedings of the National Academy of Sciences, 2006